Work

Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial

Year: 2024

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Diabetes & Endocrinology

DOI: 10.1016/s2213-8587(24)00150-5

Authors: Allison Ross Eckard, Qian Wu, Abdus Sattar, Kianoush Ansari-Gilani, Danielle Labbato, Theresa Foster, Aaron A Fletcher, Ruth O Adekunle, Grace A McComsey

Institutions: Medical University of South Carolina, Case Western Reserve University, University Hospitals Cleveland Medical Center, University Hospitals of Cleveland

Language: English

Topic: HIV-related health complications and treatments

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Gilead Sciences, National Institutes of Health, Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences

Awards: Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy, G7888544820, Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages for Everyone's Health (CLE Health)

OpenAlex ID: W4400178611

FWCI: 19.53

Cites: 31

Cited by: 65

Related to: 10